Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (443)	6/15/1999 8:55:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 3158

Remember SUGN touched single digits at the end of last summer. Close on a 40% premium over the current price is something I will accept fairly happily with my few shares of common - no option holding for me on this one, alas. I guess I'm a little surprised at the timing - would have thought SUGN might have waited a year or so before selling. The interesting thing is that PNU was prepared to undergo some minor dilution for a year or so - shows the pharma are prepared to move a little further down the food chain than was the case with AGPH. This plus the GNE buyout/IPO should help the sector over the next few months. I think GNE is going to be a bigger deal for the sector than one might think - it might actually be a hot IPO if Roche doesn't get too greedy. Peter

To: scaram(o)uche who wrote (443)	6/16/1999 12:45:00 AM
From: margie	Read Replies (1) \| Respond to of 3158

No, Richard, I meant to buy a long time ago but never got around to it. I was always impressed with the company, the science, AND their lack of hype. OTOH, reading the press release was like deja vu and I will not miss having to deal with another merger like Agouron's. That was enough for me, I really never thought that Agouron would be bought out. The shorts were wrong with agph too. Unfortunately, they didn't have to pay much. At one point Agouron had over 7 million shares short, maybe 8 million short; out of 31 million outstanding shares. BTW, I can't say I was sorry to hear about all the redemption's from the Tiger fund. (Julian Robertson is Tiger Fund's manager and apparently Tiger Fund had a large short position in Agouron. So did the Prudent Bear, aka David Tice.) Here's a piece from Cramer, feeling sorry for Robertson. thestreet.com <Random musings: What a crummy business this is that Julian Robertson (from has redemptions after a subpar quarter. I know a ton of people in this business. Every hire I have ever seen this guy make is the best guy in the biz. His numbers are extraordinary. His charity is, quite simply, unbelievable. (I am on the board of a small charity, and he leased us one of his charity staffers just to help us off the ground. She was about as impressive as I have ever seen in business, and her business was making public schools better by working with the system.). He is the best. His investors want out? I want in! > What kind of charitable person shorts the stocks of great biotech companies developing products for AIDS, cancer, and other diseases. Charitable, my @#$! It's just too bad that good biotech companies aren't rewarded more, and I'm not referring to the buyout price or premium.